Medical Central Oxygen Supply System MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy ApplicationBy End-userBy System TypeBy Component
Full title & scope — all 5 axes with their segments
Medical Central Oxygen Supply System Market Size, Share & Industry Analysis, By Product Type (Pure Medical Gases, Medical Gas Mixtures, Compressors, Cylinders, Hose Assemblies and Valves, Masks, Vacuum Systems, Regulator, Others), By Application (Therapeutic, Diagnostics, Others), By End-user (Hospitals, Ambulatory Surgical Centers, Diagnostic and Research Laboratories, Others), By System Type (Liquid Oxygen (VIE) Systems, PSA Oxygen Generator Systems, Cylinder Manifold Systems), By Component (Equipment, Installation and Commissioning Services, Maintenance and Aftermarket Services), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By Product TypePure Medical Gases · Medical Gas Mixtures · Compressors
- 02By ApplicationTherapeutic · Diagnostics · Others
- 03By End-userHospitals · Ambulatory Surgical Centers · Diagnostic and Research Laboratories
- 04By System TypeLiquid Oxygen · PSA Oxygen Generator Systems · Cylinder Manifold Systems
- 05By ComponentEquipment · Installation and Commissioning Services · Maintenance and Aftermarket Services
- 06By Region
Market Analysis & Outlook
A medical central oxygen supply system delivers medical-grade oxygen from a single source, whether a liquid oxygen tank, an on-site pressure swing adsorption generator, or a cylinder manifold, through a piped distribution network to multiple points of use within a healthcare facility. The category covers the generation or storage equipment, the compressors and vacuum components that maintain pressure and flow, and the valves, regulators and outlet fittings that connect the network to bedside and procedure-room terminals. Buyers are hospitals, ambulatory surgical centers and diagnostic facilities that need continuous, code-compliant oxygen delivery instead of relying on individual portable cylinders.
The global medical central oxygen supply system market is valued at USD 440 million in 2025 and is set to reach USD 966 million by 2034, a compound annual growth rate of 9.14% across the 2026-2034 forecast period. The study tracks the market across USD 280 million in 2020, USD 400 million in 2024, USD 480 million in 2026 and USD 682 million in 2030.
20% of 2025 revenue sits in Cylinders, worth USD 88 million and rising to USD 154.6 million at 16% by 2034, the largest product type line in both years. Growth is fastest in Compressors at 14.03% and slowest in Cylinders at 6.43%. The lines gaining share are Compressors, Vacuum Systems and Regulator. Pure Medical Gases, Medical Gas Mixtures, Cylinders, Hose Assemblies and Valves, Masks and Others lose share without losing revenue.
The application split puts Therapeutic first, at USD 343.2 million and 78% of revenue in 2025, rising to USD 734.2 million and 76% in 2034. Others grows faster at 10.75% against 8.82%, moving from 7% of revenue to 7.99% by 2034. It cuts the same total as the product type axis from a different commercial angle, so revenue does not add across the two.
The regional order runs from Asia Pacific at 30% of 2025 revenue down to Latin America at 8%. Asia Pacific is worth USD 132 million in 2025 and USD 328.4 million in 2034; North America, second at 28%, moves from USD 123.2 million to USD 231.8 million. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.
The 2025 total is triangulated from published sources and category proxies, with no independently sourced count behind it. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, nine product type lines and five segmentation axes across a fifteen-year window.
Market Size, 2020–2034
USD MillionRevenue in USD Million. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 9.14% takes the market from USD 440 million in 2025 to USD 966 million in 2034, against 9.47% recorded over the 2020-2025 historical period.
- Cylinders is the largest product type line at USD 88 million in 2025, a 20% share, reaching USD 154.6 million and 16% of revenue by 2034.
- At 14.03%, Compressors grows faster than any other product type line, moving from USD 70.4 million and 16% of revenue in 2025 to USD 231.8 million and 24% in 2034.
- The bull case puts 2034 revenue at USD 1050 million and the bear case at USD 866 million, either side of the USD 966 million base case, each with its own stated assumption in the full report.
- The largest region is Asia Pacific, generating USD 132 million in 2025 (30% of the global total) and USD 328.4 million by 2034, ahead of North America at 28%.
- China accounts for 38% of Asia Pacific in the base year, worth USD 50.2 million in 2025 and reaching USD 111.7 million by 2034, the worked country example carried through that region's chapters.
- Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By By Product Type
Base year 2025Cylinders leads with 20.0% of by product type segment revenue.
Share of by product type segment revenue, most recent base year. The 3 smallest segments are grouped as Other.
The global medical central oxygen supply system market is shaped over 2026-2034 by three measurable movements: a change in the product type mix, a shift in where revenue sits geographically, and the 9.14% rate carrying the total.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Compressors outpaces Cylinders. 14.03% against 6.43%: that gap, between Compressors and Cylinders, is the largest on the product type axis. Shares follow: 16% to 24% for Compressors, 20% to 16% for Cylinders. Neither contracts: USD 70.4 million becomes USD 231.8 million, USD 88 million becomes USD 154.6 million. What the spread decides is which of them a supplier's revenue is exposed to.
Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 30% of revenue in 2025 to 34% in 2034, worth USD 132 million rising to USD 328.4 million; Latin America moves from 8% of revenue in 2025 to 9% in 2034, worth USD 35.2 million rising to USD 86.9 million; Middle East and Africa moves from 10% of revenue in 2025 to 13% in 2034, worth USD 44 million rising to USD 125.7 million. The offsetting side is North America at 28% moving to 24%, Europe at 24% moving to 20%, none of which contracts. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.
Growth compounds at 9.14% without a step change. Year by year the total runs USD 280 million in 2020, USD 400 million in 2024, USD 440 million in 2025, USD 480 million in 2026, USD 682 million in 2030 and USD 966 million in 2034. The forecast rate of 9.14% sits against 9.47% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product type and regional axes, not by the headline rate.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
At 14.03% against a market rate of 9.14%, Compressors is the line pulling the average up: USD 70.4 million to USD 231.8 million, and 16% of revenue to 24%. The market's overall 9.14% depends on that rate holding: at the 6.43% recorded by Cylinders, the same revenue base would compound to a materially smaller 2034 total. Exposure to this line, not to the market as a whole, is what determines a supplier's own rate.
- 02Asia Pacific carries 30% of the base and keeps growing
Asia Pacific is the largest region at USD 132 million in 2025, 30% of global revenue, and reaches USD 328.4 million by 2034 on a share rising to 34%. North America adds a further 28% at USD 123.2 million, reaching USD 231.8 million. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03The trend is already in the record
Revenue rose through USD 280 million in 2020, USD 400 million in 2024 and USD 440 million in 2025, a compound 9.47% across the historical period. The forecast period then runs at 9.14%, ending 2034 at USD 966 million. Fifteen years of unbroken growth in the series means the forecast rests on a demonstrated trajectory, not a projected turnaround, and it is why the 9.14% rate is applied flat across the whole period instead of ramped through it.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Million) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | On-site oxygen generation adoption following supply disruptions | High | +180 | High | High | Medium |
| 2 | Hospital bed and ICU capacity expansion in emerging markets | Medium-High | +120 | High | Medium | Medium |
| 3 | Medical gas pipeline safety and redundancy requirements | Medium | +90 | Medium | Medium | Medium |
| 4 | Ambulatory surgical center construction growth | Medium | +70 | Low | Medium | Medium |
| 5 | Replacement of aging liquid oxygen and manifold installations | Medium | +60 | Medium | Medium | High |
| 6 | Others | Low | +46 | Low | Low | Low |
| Total | +566 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Million) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Capital cost of on-site generation systems | Medium | −25 | Medium | Medium | Low |
| 2 | Price competition from bulk liquid oxygen delivery contracts | Low | −15 | Low | Low | Low |
| Total | −40 | |||||
Drivers contribute 566 Million and restraints remove 40 Million, a net 526 Million, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 9.14% into its parts and three show up: an already-large base compounding, the product type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
Downside case: USD 866 million by 2034, against USD 966 million in the base case
Market Restraints
2- 01Downside case: USD 866 million by 2034, against USD 966 million in the base case
A bear case of USD 866 million in 2034, against USD 966 million in the base case, rests on one stated assumption: hospital capital spending is constrained by broader public health budget pressure, slowing both new installations and the conversion from cylinder and liquid oxygen systems to on-site generation. Neither case changes the USD 440 million 2025 base.
- 02Cylinders grows below the market rate
Cylinders carries 20% of 2025 revenue at USD 88 million but compounds at 6.43% against 9.14% for the market, taking its share to 16% by 2034 even as revenue rises to USD 154.6 million. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
What would beat the forecast: hospital capital budgets accelerate faster than assumed, and on-site generator adoption in cost-constrained markets moves faster than the base case. That case reaches USD 1050 million in 2034 against USD 966 million, and it is worth testing against a reader's own read of the market.
- 02The opening is on the product type axis, not the regional one
Share on the product type axis moves toward Compressors, from 16% in 2025 to 24% in 2034, on 14.03% growth against the market's 9.14% and revenue rising from USD 70.4 million to USD 231.8 million. Taking position there does not require displacing whoever holds Cylinders, which is the harder and more expensive fight.
Market Challenges
Concentration on the product type axis
Market Challenges
2- 01Concentration on the product type axis
USD 88 million of 2025 revenue sits in Cylinders, 20% of the total, and it is still 16% at USD 154.6 million nine years later. Anything that changes demand for it changes the headline number; nothing else on the axis carries that weight.
- 02Single-country exposure in Asia Pacific
Of Asia Pacific's USD 132 million in 2025, USD 50.2 million (38%) comes from China alone, rising to USD 111.7 million by 2034. Read as a region it looks diversified; read by weight it is not, and the regional forecast inherits whatever happens in that one market.
Segmentation Analysis
5 axesSegmentation runs along five axes: product type, application, end-user, system type and component. Revenue does not add across them: each is a different cut of the same total.
Nine product type lines are reported. Three of them take share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Product Type · 9 segments
By Product Type
- Largest Cylinders · 20%
- Fastest Compressors · 14%
- Moves most Compressors · +8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pure Medical Gases | $79.20M | 18% | $145M | 15%-3 | 6.9% |
| Medical Gas Mixtures | $26.40M | 6% | $48.30M | 5%-1 | 6.9% |
| Compressors | $70.40M | 16% | $232M | 24%+8 | 14% |
| Cylinders | $88M | 20% | $155M | 16%-4 | 6.4% |
| Hose Assemblies and Valves | $44M | 10% | $86.90M | 9%-1 | 7.8% |
| Masks | $35.20M | 8% | $67.60M | 7%-1 | 7.5% |
| Vacuum Systems | $52.80M | 12% | $126M | 13%+1 | 10.1% |
| Regulator | $30.80M | 7% | $77.30M | 8%+1 | 10.8% |
| Others | $13.20M | 3% | $29M | 3% | 9.3% |
2025 to 2034 revenue and share by line: Cylinders USD 88 million to USD 154.6 million (20% in 2025), Pure Medical Gases USD 79.2 million to USD 144.9 million (18% in 2025), Compressors USD 70.4 million to USD 231.8 million (16% in 2025), Vacuum Systems USD 52.8 million to USD 125.6 million (12% in 2025), Hose Assemblies and Valves USD 44 million to USD 86.9 million (10% in 2025), Masks USD 35.2 million to USD 67.6 million (8% in 2025), Regulator USD 30.8 million to USD 77.3 million (7% in 2025), Medical Gas Mixtures USD 26.4 million to USD 48.3 million (6% in 2025), Others USD 13.2 million to USD 29 million (3% in 2025). Compressors Outpaces the Axis While Cylinders Holds the Largest Share Cylinders lead because they remain the widest installed base across facilities that have not converted to on-site generation, and they serve as the standard backup for any central system regardless of its primary source. Compressors grow fastest as hospitals invest in pressure swing adsorption generation to reduce dependence on delivered liquid oxygen and cylinder refills, a shift accelerated by the supply disruptions several facilities experienced during recent public health emergencies. By 2034 the largest line is Compressors and no longer Cylinders, the one axis here where the order actually changes. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Application · 3 segments
Therapeutic Led by Application in 2025, with Others Growing Fastest
- Largest Therapeutic · 78%
- Fastest Others · 10.8%
- Moves most Therapeutic · -2 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Therapeutic | $343M | 78% | $734M | 76%-2 | 8.8% |
| Diagnostics | $66M | 15% | $155M | 16%+1 | 9.9% |
| Others | $30.80M | 7% | $77.20M | 8%+1 | 10.8% |
Therapeutic use leads because central oxygen systems are installed primarily to support continuous patient respiratory therapy and ventilation across wards and critical care areas, and this demand holds regardless of discretionary spending cycles. Diagnostics grows fastest as imaging and procedural suites increasingly draw on the same central supply instead of standalone cylinders, extending the system's use beyond bedside therapy. The order does not change: Therapeutic is still largest in 2034, and what moves is how much it holds.
By End-user · 4 segments
Ambulatory Surgical Centers Outpaces the Axis While Hospitals Holds the Largest Share
- Largest Hospitals · 68%
- Fastest Ambulatory Surgical Centers · 11.4%
- Moves most Hospitals · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals | $299M | 68% | $618M | 64%-4 | 8.4% |
| Ambulatory Surgical Centers | $66M | 15% | $174M | 18%+3 | 11.4% |
| Diagnostic and Research Laboratories | $44M | 10% | $106M | 11%+1 | 10.3% |
| Others | $30.80M | 7% | $67.60M | 7% | 9.1% |
Hospitals lead because central oxygen supply is core life-support infrastructure installed at the facility level, covering wards, operating theatres and emergency departments simultaneously. Ambulatory surgical centers grow fastest as outpatient surgical volumes shift away from inpatient hospitals, and these facilities install dedicated central systems instead of equipping each procedure room with portable cylinders. By 2034 Hospitals is still ahead, making this a shift in weight, not a change of leader.
By System Type · 3 segments
PSA Oxygen Generator Systems Outpaces the Axis While Liquid Oxygen (VIE) Systems Holds the Largest Share
- Largest Liquid Oxygen (VIE) Systems · 42%
- Fastest PSA Oxygen Generator Systems · 12.1%
- Moves most PSA Oxygen Generator Systems · +9 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Liquid Oxygen (VIE) Systems | $185M | 42% | $348M | 36%-6 | 7.3% |
| PSA Oxygen Generator Systems | $145M | 33% | $406M | 42%+9 | 12.1% |
| Cylinder Manifold Systems | $110M | 25% | $213M | 22%-3 | 7.6% |
Liquid oxygen systems lead because they remain the established standard for large hospitals with continuous, high-volume demand and existing vacuum-insulated evaporator infrastructure already in place. On-site generator systems grow fastest as facilities seeking independence from tanker deliveries and price volatility install pressure swing adsorption plants, a shift reinforced by the supply disruptions many hospitals experienced during recent public health emergencies. Leadership changes hands: PSA Oxygen Generator Systems is the largest line by 2034, not Liquid Oxygen (VIE) Systems.
By Component · 3 segments
Maintenance and Aftermarket Services Outpaces the Axis While Equipment Holds the Largest Share
- Largest Equipment · 58%
- Fastest Maintenance and Aftermarket Services · 12.2%
- Moves most Maintenance and Aftermarket Services · +5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Equipment | $255M | 58% | $522M | 54%-4 | 8.3% |
| Installation and Commissioning Services | $106M | 24% | $222M | 23%-1 | 8.6% |
| Maintenance and Aftermarket Services | $79.20M | 18% | $222M | 23%+5 | 12.2% |
Equipment leads because a central oxygen supply installation still requires the underlying generator, manifold, piping and vacuum plant purchase before any service can attach to it. Maintenance and aftermarket services grow fastest as the installed base of systems from the past decade ages into recurring servicing, calibration and component replacement cycles; equipment sales lead the cycle and service revenue follows behind it. Equipment remains the largest line through 2034, so the axis changes in proportion, not in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The 2nd-largest region covered, and the one giving up the most — 4 points of share move elsewhere by 2034, while revenue still grows 1.9×.
- Rank 2 of 5
- 2025 share 28%
- By 2034 24%
- Revenue $123M → $232M
28% of the global medical central oxygen supply system market sits in North America in 2025, worth USD 123.2 million and reaches USD 231.8 million by 2034. It is a leading region on this axis, second by revenue throughout the period.
By 2034 the share stands at 24%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
The product type mix reported at global level applies here, with Cylinders the largest line at 20% of 2025 revenue and Compressors the fastest-growing at 14.03%. Revenue for North America is broken out by every segmentation axis and by country in the full report.
United States
Sets the pace for North America at 85% of it, growing 1.9×.
- In region 1 of 2
- Of region 85%
- Of global 23.8%
- Revenue $105M → $197M
85% of North America's base-year revenue comes from the United States; USD 104.7 million, rising to USD 197 million by 2034. 85% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 123.2 million and USD 231.8 million for the region, it is why this market, and not a smaller one, is the one reported in full.
the United States buys along the same lines as the market globally; Cylinders first at 20% of 2025 revenue and 16% in 2034, Compressors fastest at 14.03% on a share moving from 16% to 24%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own product type breakdown in the full report.
Central oxygen supply systems installed in hospitals fall under the Food and Drug Administration as medical devices, since the piping, manifolds, alarms, and outlets that deliver medical gas to patient care areas are regulated components rather than mere plumbing. Manufacturers must classify the system correctly and clear it through the applicable premarket pathway before sale, then meet FDA quality system requirements covering design controls, manufacturing, and labelling. Facility-level installation is additionally governed by NFPA standards for medical gas and vacuum systems, which set requirements for source equipment, distribution piping, alarm systems, and verification testing, and hospitals must maintain compliance with these standards to satisfy accreditation and life-safety inspections. Oxygen itself is treated as a prescription drug subject to current good manufacturing practice, so the purity and delivery chain are both regulated in parallel.
Competition in the United States runs between the suppliers this study tracks: PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. Volume sits in Cylinders at 20% of 2025 revenue; movement sits in Compressors at 14.03% growth. Country-level shares and positioning per company sit in the full report.
Canada
2nd-largest in North America, growing 1.9×.
- In region 2 of 2
- Of region 13%
- Of global 3.6%
- Revenue $16M → $30.10M
Within North America, Canada accounts for 13% of regional revenue and 3.6% of the global total, worth USD 16 million in 2025 and USD 30.1 million by 2034.
Europe Market Analysis
The 3rd-largest region covered — 4 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 20%
- Revenue $106M → $193M
USD 105.6 million of 2025 revenue is generated in Europe, 24% of the global medical central oxygen supply system market rising to USD 193.2 million in 2034. That makes it the third-largest region covered, in 2025 and again in 2034.
Its share moves to 20% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The product type mix reported at global level applies here, with Cylinders the largest line at 20% of 2025 revenue and Compressors the fastest-growing at 14.03%. Per-axis and per-country detail for Europe sits in the full report.
Germany
The largest market in Europe, growing 1.8×.
- In region 1 of 3
- Of region 30%
- Of global 7.2%
- Revenue $31.70M → $58M
30% of Europe's base-year revenue comes from Germany; USD 31.7 million, rising to USD 58 million by 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 105.6 million in 2025 and USD 193.2 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Composition here matches the global split: the largest line is Cylinders at 20% of 2025 revenue, easing to 16% by 2034, and the fastest is Compressors at 14.03%, from 16% to 24%. Its 30% weight in Europe means those movements carry straight into the regional totals. Germany carries its own product type breakdown in the full report.
Central oxygen supply systems in Germany are regulated as medical devices under the EU Medical Device Regulation, which governs the manifolds, pipeline networks, alarm units, and terminal outlets that make up the installed system. A supplier must hold a valid conformity assessment, affix CE marking, and maintain technical documentation demonstrating conformity with the harmonised standard covering pipeline systems for medical gases before the system can be placed on the market or put into service. Installation and ongoing operation are further governed by German medical device operator regulations, which impose maintenance, testing, and record-keeping duties on the operating hospital. Medicinal oxygen supplied through the system is separately regulated as a pharmaceutical product, so its manufacture and distribution fall under German pharmaceutical law and are overseen by the competent federal authority.
Competition in Germany runs between the suppliers this study tracks: PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. Cylinders, at 20% of 2025 revenue, is where the volume sits, and Compressors, growing at 14.03%, is where position changes hands over the forecast period. The commercial size of that position is USD 105.6 million in 2025, moving to USD 193.2 million by 2034 across the forecast period.
United Kingdom
2nd-largest in Europe, growing 1.8×.
- In region 2 of 3
- Of region 22%
- Of global 5.3%
- Revenue $23.20M → $42.50M
The United Kingdom is sized at USD 23.2 million in 2025, rising to USD 42.5 million by 2034; 5.3% of global revenue and 22% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 1.8×.
- In region 3 of 3
- Of region 16%
- Of global 3.8%
- Revenue $16.90M → $30.90M
Within Europe, France accounts for 16% of regional revenue and 3.8% of the global total, worth USD 16.9 million in 2025 and USD 30.9 million by 2034.
Asia Pacific Market Analysis
The largest region covered — it picks up 4 points of share by 2034, while revenue still grows 2.5×.
- Rank 1 of 5
- 2025 share 30%
- By 2034 34%
- Revenue $132M → $328M
30% of the global medical central oxygen supply system market sits in Asia Pacific in 2025, worth USD 132 million on the way to USD 328.4 million by 2034. It is a leading region on this axis, first by revenue throughout the period.
Share climbs to 34% by 2034, so the region grows faster than the market's 9.14% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Segment composition follows the global pattern: Cylinders largest at 20% of 2025 revenue, Compressors fastest at 14.03%. The full report breaks Asia Pacific out along every axis and by country.
China
The largest market in Asia Pacific, growing 2.2×.
- In region 1 of 3
- Of region 38%
- Of global 11.4%
- Revenue $50.20M → $112M
China is the largest market within Asia Pacific, generating USD 50.2 million in 2025 and projected to reach USD 111.7 million by 2034. At 38% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Set against USD 132 million and USD 328.4 million for the region, it is why this market, and not a smaller one, is the one reported in full.
China buys along the same lines as the market globally; Cylinders first at 20% of 2025 revenue and 16% in 2034, Compressors fastest at 14.03% on a share moving from 16% to 24%. Since 38% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-product type revenue for China appears on its own in the full report.
China regulates central oxygen supply systems as medical devices under the National Medical Products Administration, which assigns a risk classification to the pipeline network, manifold, and alarm components and requires registration before the system may be marketed or installed. Registration requires the manufacturer to submit technical and clinical evidence appropriate to the assigned class, and the finished system must conform to national standards covering medical gas pipeline installations, including provisions for pressure, alarm function, and terminal unit design. Manufacturing facilities are subject to inspection against China's medical device quality management regulations, and imported systems must additionally go through a registered in-country agent. Oxygen gas supplied through the system is regulated separately as a pharmaceutical product, placing its production and distribution under pharmaceutical administration rules enforced alongside the device framework.
In China the field is PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. Volume sits in Cylinders at 20% of 2025 revenue; movement sits in Compressors at 14.03% growth. A supplier weighted toward Asia Pacific is competing over a base of USD 132 million in 2025, reaching USD 328.4 million by 2034 on the trajectory this study models.
India
2nd-largest in Asia Pacific, growing 3.2×.
- In region 2 of 3
- Of region 22%
- Of global 6.6%
- Revenue $29M → $92M
India is sized at USD 29 million in 2025, rising to USD 92 million by 2034; 6.6% of global revenue and 22% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Japan
3rd-largest in Asia Pacific, growing 2.0×.
- In region 3 of 3
- Of region 15%
- Of global 4.5%
- Revenue $19.80M → $39.40M
Within Asia Pacific, Japan accounts for 15% of regional revenue and 4.5% of the global total, worth USD 19.8 million in 2025 and USD 39.4 million by 2034.
Latin America Market Analysis
The 5th-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 2.5×.
- Rank 5 of 5
- 2025 share 8%
- By 2034 9%
- Revenue $35.20M → $86.90M
USD 35.2 million of 2025 revenue is generated in Latin America, 8% of the global medical central oxygen supply system market and reaches USD 86.9 million by 2034. Among the five regions it ranks fifth by revenue in both years.
Its share rises to 9% over the forecast period, on growth above the market's own 9.14%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
The product type mix reported at global level applies here, with Cylinders the largest line at 20% of 2025 revenue and Compressors the fastest-growing at 14.03%. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 2.5×.
- In region 1 of 2
- Of region 44.9%
- Of global 3.6%
- Revenue $15.80M → $39.10M
The largest single market in Latin America is Brazil, at USD 15.8 million in 2025 and USD 39.1 million in 2034. At 44.9% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Regional revenue of USD 35.2 million in 2025 and USD 86.9 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in Brazil follows the product type mix reported at global level: Cylinders is the largest line at 20% of 2025 revenue, moving to 16% by 2034, while Compressors grows fastest at 14.03% and takes its share from 16% to 24%. Since 44.9% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports Brazil by product type separately.
Central oxygen supply systems in Brazil are regulated by ANVISA, the national health surveillance agency, which classifies the pipeline, manifold, alarm, and outlet components as medical devices requiring registration before commercial distribution or installation. Registration requires evidence of conformity with applicable technical standards for medical gas pipeline systems, and manufacturing sites are subject to good manufacturing practice certification issued or recognised by ANVISA. Facilities operating these systems must additionally comply with health surveillance rules governing hospital infrastructure, including periodic testing and maintenance of piping and alarm integrity to retain operating authorisation. Medicinal oxygen delivered through the system is regulated as a pharmaceutical product in its own right, so the gas supply chain sits under separate pharmaceutical oversight even where the physical delivery system shares the same installation.
In Brazil the field is PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. The commercially relevant division is 20% of 2025 revenue in Cylinders, where the volume is, against 14.03% growth in Compressors, where share moves. The commercial size of that position is USD 35.2 million in 2025, moving to USD 86.9 million by 2034 across the forecast period.
Mexico
2nd-largest in Latin America, growing 2.5×.
- In region 2 of 2
- Of region 30.1%
- Of global 2.4%
- Revenue $10.60M → $26.10M
2.4% of global revenue is generated in Mexico; USD 10.6 million in 2025, reaching USD 26.1 million in 2034, and 30.1% of Latin America.
Middle East and Africa Market Analysis
The 4th-largest region covered — it picks up 3 points of share by 2034, while revenue still grows 2.9×.
- Rank 4 of 5
- 2025 share 10%
- By 2034 13%
- Revenue $44M → $126M
USD 44 million of 2025 revenue is generated in Middle East and Africa, 10% of the global medical central oxygen supply system market rising to USD 125.7 million in 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.
Its share rises to 13% over the forecast period, on growth above the market's own 9.14%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Within the region the product type split tracks the global one; 20% of 2025 revenue in Cylinders, fastest growth of 14.03% in Compressors. Middle East and Africa is reported axis by axis and country by country in the full study.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.9×.
- In region 1 of 2
- Of region 28%
- Of global 2.8%
- Revenue $12.30M → $35.20M
The largest single market in Middle East and Africa is Saudi Arabia, at USD 12.3 million in 2025 and USD 35.2 million in 2034. At 28% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 44 million in 2025 and USD 125.7 million in 2034, it is the country the full report breaks out in detail.
Saudi Arabia buys along the same lines as the market globally; Cylinders first at 20% of 2025 revenue and 16% in 2034, Compressors fastest at 14.03% on a share moving from 16% to 24%. Because the country carries 28% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-product type revenue for Saudi Arabia appears on its own in the full report.
In Saudi Arabia, central oxygen supply systems are regulated as medical devices by the Saudi Food and Drug Authority, which requires the manufacturer or an authorised local representative to register the system before it can be marketed, imported, or installed in a healthcare facility. Registration follows a risk-based classification route and requires technical documentation showing conformity with recognised international standards for medical gas pipeline systems, alarm units, and terminal outlets. Installed systems are also subject to facility licensing requirements administered through the Ministry of Health, which reviews medical gas infrastructure as part of hospital accreditation and ongoing inspection. Medicinal oxygen supplied through the pipeline is treated as a pharmaceutical product and regulated separately from the physical delivery hardware, consistent with the dual device-and-drug oversight seen in other major markets.
Competition in Saudi Arabia runs between the suppliers this study tracks: PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries. Cylinders, at 20% of 2025 revenue, is where the volume sits, and Compressors, growing at 14.03%, is where position changes hands over the forecast period. The commercial size of that position is USD 44 million in 2025, moving to USD 125.7 million by 2034 across the forecast period.
South Africa
2nd-largest in Middle East and Africa, growing 2.9×.
- In region 2 of 2
- Of region 18%
- Of global 1.8%
- Revenue $7.90M → $22.60M
1.8% of global revenue is generated in South Africa; USD 7.9 million in 2025, reaching USD 22.6 million in 2034, and 18% of Middle East and Africa.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product Type, Application, End-User, System Type, Component, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Product type Axis Decides Competitive Standing
Suppliers in scope: PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI and Chart Industries.
The product type axis, not the regional one, is where competition happens. Volume sits in Cylinders, USD 88 million and 20% of 2025 revenue, 16% by 2034, which is also where an incumbent is hardest to dislodge. Compressors, compounding at 14.03% against 6.43% for Cylinders, is where share changes hands over the forecast period. Those are different problems, and a supplier strong in one is not thereby strong in the other; that is what sustains a field this size in a USD 440 million market.
Competition in central oxygen supply centers on regulatory and installation credentials rather than brand alone: suppliers need certified pipeline design and commissioning capability to meet hospital life-safety codes, since an approval failure delays a facility's opening. The largest players combine generator manufacturing with pipeline installation and long-term maintenance contracts, giving them recurring service revenue and an incumbent position when a facility expands. Smaller and regional manufacturers compete on faster local service response, lower-volume project pricing and close relationships with individual health authorities or hospital groups, particularly in markets where a facility prefers a domestic supplier for after-sales support and spare-parts availability.
The regional picture sets the entry cost: 30% of revenue is in Asia Pacific and 28% in North America, so a credible global position requires both, while Latin America at 8% can be served opportunistically.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Medical Central Oxygen Supply System Market Companies Profiled
7 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- PCI Gases(United States)
- Oxyplus Technologies (NOVAIR)(France)
- Oxymat A/S(Denmark)
- Oxair(United Kingdom)
- On Site Gas Systems(United States)
- OGSI(United States)
- Chart Industries(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Product Type, Application, End-user, System Type, Component), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 7 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Medical Central Oxygen Supply System Market Size & Projections, 2020–2034, Revenue (USD Million)
Chapter 16.Global Medical Central Oxygen Supply System Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
Chapter 17.Global Medical Central Oxygen Supply System Market Overview, By Application, 2020–2034, Revenue (USD Million)
Chapter 18.Global Medical Central Oxygen Supply System Market Overview, By End-user, 2020–2034, Revenue (USD Million)
Chapter 19.Global Medical Central Oxygen Supply System Market Overview, By System Type, 2020–2034, Revenue (USD Million)
Chapter 20.Global Medical Central Oxygen Supply System Market Overview, By Component, 2020–2034, Revenue (USD Million)
Chapter 21.Global Medical Central Oxygen Supply System Market Size — Segment Comparison
Chapter 22.Global Medical Central Oxygen Supply System Geography Overview, 2020–2034, Revenue (USD Million)
Chapter 23.North America Medical Central Oxygen Supply System Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 24.Europe Medical Central Oxygen Supply System Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 25.Asia Pacific Medical Central Oxygen Supply System Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 26.Latin America Medical Central Oxygen Supply System Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 27.Middle East and Africa Medical Central Oxygen Supply System Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Product Type
9- 01Pure Medical Gases
- 02Medical Gas Mixtures
- 03Compressors
- 04Cylinders
- 05Hose Assemblies and Valves
- 06Masks
- 07Vacuum Systems
- 08Regulator
- 09Others
By Application
3- 01Therapeutic
- 02Diagnostics
- 03Others
By End-user
4- 01Hospitals
- 02Ambulatory Surgical Centers
- 03Diagnostic and Research Laboratories
- 04Others
By System Type
3- 01Liquid Oxygen (VIE) Systems
- 02PSA Oxygen Generator Systems
- 03Cylinder Manifold Systems
By Component
3- 01Equipment
- 02Installation and Commissioning Services
- 03Maintenance and Aftermarket Services
Segment categories shown for scope reference. See the Summary tab for revenue share by By Product Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from the number of central oxygen systems installed each year, split by system type: liquid oxygen plants, pressure swing adsorption generator skids and cylinder manifold rooms. Each installation count is multiplied by average unit pricing, which varies by generator capacity in normal cubic meters per hour, piping run length and commissioning labor. This unit-and-price build is then checked against the disclosed equipment and service revenue of the manufacturers named in this report and against shipment volumes recorded under the compressor and gas-generation equipment trade codes. Where a facility-count assumption produced a build that diverged from a manufacturer's disclosed regional revenue, the installation-volume assumption was the input corrected, not the disclosed figure.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary outreach targets hospital facilities and biomedical engineering managers who specify and maintain central oxygen infrastructure, procurement officers at multi-site hospital groups who negotiate equipment and service contracts, and channel partners such as medical gas system integrators who install and commission these systems on the manufacturer's behalf. Regulatory affairs contacts at national health authorities are included where central gas pipeline codes require government sign-off before a system is commissioned. Sampling weights toward North America and Europe, where installed-base replacement is the dominant driver and facility contacts are more reachable, alongside a targeted sample in Asia Pacific and the Middle East, where new hospital construction is expanding fastest.
Desk research draws on national medical device and pressure-equipment registries where central oxygen generators and manifolds require separate certification from portable cylinders, hospital capital-expenditure disclosures and tender records published by public health authorities for new facility construction, and customs classifications covering compressors, gas-separation equipment and cryogenic storage vessels. Trade-association benchmarks from medical gas industry bodies in North America and Europe supply typical installation costs per bed and per facility type. Published clearance and conformity filings for oxygen generator equipment, required before a system can be installed in a hospital, are cross-checked against the installation-volume assumptions used in the bottom-up build.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from projected hospital bed growth and new facility construction by region, combined with the pace at which existing liquid oxygen and cylinder manifold installations are converted to on-site generation. Pricing is held broadly flat in real terms, since generator equipment costs have not shown a sustained inflation or deflation trend, while installation and commissioning labor costs are assumed to track regional wage growth. The 2021 to 2022 period is normalized for the exceptional oxygen-capacity investment triggered by pandemic-related demand spikes, since that surge does not represent a repeatable annual pattern. The forecast holds only if hospital capital budgets continue to prioritize supply-security infrastructure over the study period.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs are back-tested against recorded hospital construction and healthcare capital-expenditure growth for 2020 through 2024 to confirm the historical build does not diverge from independently reported infrastructure spending. Segment-level shifts, particularly the transition from cylinder manifold systems toward on-site generation, were reviewed against the installation and service contract mix reported by the manufacturers named in this report. Sensitivities were run on the generator-adoption rate and on regional hospital construction pipelines, the two assumptions most likely to move the forecast if either proves faster or slower than assumed. A scenario where generator adoption stalls in cost-constrained markets was tested separately to confirm the bear case still holds.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is strongest for the system-type split and for North America and Europe, where installed-base replacement patterns are well documented and the manufacturer base is concentrated enough to triangulate against. It is weaker for Middle East and Africa country-level figures, where new hospital construction pipelines are reported unevenly and generator adoption data is thinner. The application and end-user splits rest more on proxy reasoning than on direct disclosure, since few suppliers report revenue at that level of detail. A material change in public hospital capital budgets in any single large market, particularly a country carrying an outsized regional share, would be the most likely trigger for revision.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Medical Central Oxygen Supply System Market projected to reach?
USD 966 Million by 2034, CAGR 9.14%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
Asia Pacific leads with 30% of global revenue through 2034.
05Which segment leads the market?
Cylinders is the largest line by Product Type, at 20% of revenue in 2025.
06Who are the key companies profiled?
PCI Gases, Oxyplus Technologies (NOVAIR), Oxymat A/S, Oxair, On Site Gas Systems, OGSI, Chart Industries. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.